Welcome to our dedicated page for Reneo Pharmaceuticals news (Ticker: RPHM), a resource for investors and traders seeking the latest updates and insights on Reneo Pharmaceuticals stock.
Reneo Pharmaceuticals Inc. reported on a pharmaceutical business historically focused on therapies for rare genetic mitochondrial diseases. Company updates centered on mavodelpar (REN001), a PPARδ agonist studied in adult patients with primary mitochondrial myopathies, and on clinical disclosures from the STRIDE and STRIDE AHEAD programs.
Recurring developments also included operating and financial results, cash-preservation actions, capital-structure disclosures, governance matters, shareholder voting items and strategic-alternative updates following the suspension of mavodelpar development activities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.